PainReform Ltd. has announced the commencement of its development plan for OcuRing™-K, an innovative, drop-less, sustained-release ocular therapy designed to deliver controlled ketorolac following cataract surgery. The company, in collaboration with LayerBio, is advancing OcuRing-K toward a Phase II clinical trial in the United States. The initial target indication is for post-cataract pain and inflammation, with the goal of providing consistent control with significantly lower drug exposure than traditional eye drops. The research and development efforts are ongoing, and future updates will be provided as the program progresses. No specific scientific research results have been presented yet; the results will be generated and shared following the next stages of clinical development.